Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma
- PMID: 19632941
- DOI: 10.3816/CLC.2009.n.033
Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma
Abstract
Background: Malignant pleural mesothelioma (MPM) is a primary malignancy characterized by local invasion of the pleura and metastasis. Despite advances in computed tomography (CT) and magnetic resonance imaging (MRI), accurately staging patients remains challenging. Recent studies have examined the use of integrated CT-positron emission tomography (PET) for staging patients.
Materials and methods: Mayo Clinic databases were queried to identify cases with a histologic diagnosis of MPM from 2000 to 2006. Inclusion criteria were a diagnosis of MPM, an available CT scan, and an initial staging integrated CT-PET scan. A total of 35 patients were identified who met the inclusion criteria. Computed tomography and integrated CT-PET scans were reviewed by experienced radiologists. Laboratory parameters were reviewed. The Mayo Clinic tumor registry and Social Security database were queried for survival data in patients in which no follow-up was available.
Results: Findings on integrated CT-PET excluded 14 of 35 patients from surgical intervention. Extrapleural pneumonectomies (EPPs) were performed in 8 patients, and partial pleurectomies were performed in 2 patients. Upstaging from integrated CT-PET occurred in 70% of the patients when surgical pathology was available, 2 cases to an inoperable stage. Although not statistically significant, median survival was 20 months for patients undergoing an EPP and 12 months for patients excluded from surgical intervention by integrated CT-PET.
Conclusion: Malignant pleural mesothelioma is a difficult disease to accurately stage. The most common reason for upstaging in our series was an increase in T (tumor; tumor-node-metastasis staging system) disease. Our data suggest that integrated CT-PET is excellent for detecting nodal and distant metastases. However, the ability of this imaging modality to correctly stage locoregional disease is not superior to the combination of CT and MRI as reported in the literature.
Similar articles
-
Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma.Thorac Cardiovasc Surg. 2010 Jun;58(4):215-9. doi: 10.1055/s-0029-1241029. Epub 2010 May 31. Thorac Cardiovasc Surg. 2010. PMID: 20514576
-
18F-fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma.J Med Imaging Radiat Oncol. 2009 Apr;53(2):160-9; quiz 170. doi: 10.1111/j.1754-9485.2009.02058.x. J Med Imaging Radiat Oncol. 2009. PMID: 19527361 Review.
-
18F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center.Br J Radiol. 2018 Jun;91(1086):20170814. doi: 10.1259/bjr.20170814. Epub 2018 Mar 29. Br J Radiol. 2018. PMID: 29498536 Free PMC article.
-
Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?Interact Cardiovasc Thorac Surg. 2011 May;12(5):806-11. doi: 10.1510/icvts.2010.255901. Epub 2011 Jan 25. Interact Cardiovasc Thorac Surg. 2011. PMID: 21266493 Review.
-
What is the best way to diagnose and stage malignant pleural mesothelioma?Interact Cardiovasc Thorac Surg. 2011 Feb;12(2):254-9. doi: 10.1510/icvts.2010.255893. Epub 2010 Nov 1. Interact Cardiovasc Thorac Surg. 2011. PMID: 21044972 Review.
Cited by
-
Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment.Mol Imaging Biol. 2011 Oct;13(5):801-11. doi: 10.1007/s11307-010-0426-6. Mol Imaging Biol. 2011. PMID: 21136185 Review.
-
Update on biology and management of mesothelioma.Eur Respir Rev. 2021 Jan 19;30(159):200226. doi: 10.1183/16000617.0226-2020. Print 2021 Mar 31. Eur Respir Rev. 2021. PMID: 33472960 Free PMC article. Review.
-
Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring.Clin Proteomics. 2013 Nov 8;10(1):16. doi: 10.1186/1559-0275-10-16. Clin Proteomics. 2013. PMID: 24207061 Free PMC article.
-
Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma.Jpn J Radiol. 2016 Aug;34(8):537-47. doi: 10.1007/s11604-016-0555-1. Epub 2016 May 24. Jpn J Radiol. 2016. PMID: 27222020 Review.
-
Malignant paratesticular mesothelioma.Autops Case Rep. 2014 Mar 31;4(1):45-51. doi: 10.4322/acr.2014.007. eCollection 2014 Jan-Mar. Autops Case Rep. 2014. PMID: 28652992 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous